lkov - adobe stock photoClinical trialsNovartis’ Ianalumab achieves Phase III e...Novartis AG has reported a clinical milestone in the treatment of Sjögren’s syndrome, with its BAFF receptor blocker Ianalumab (VAY736) becoming the first investigational therapy to demonstrate a … more ➔
Dewpoint Therapeutics IncRestructuringDewpoint Therapeutics cuts workforce, re...Dewpoint Therapeutics Inc. has announced a significant corporate restructuring. Approximately 70% of its 130 employees will be laid off, and operations will be consolidated at the company’s Boston … more ➔
adobe stock photos - ndomble RegulatoryEU Biotech Act: Have your say!The European Commission has launched a public consultation to support the development of the European Biotech Act, which is now being prioritised after a previous delay. The Commission plans to publish … more ➔
Ragon Institute/MITHIVReiThera starts study on HIV vaccineItalian biotech company ReiThera srl has commenced safety trials of its experimental HIV vaccine candidate, GRAdHIVNE1, in Harare, Zimbabwe. Developed in partnership with the Ragon Institute at Harvard … more ➔
Dr. Edwin P. Ewing, Jr. - http://phil.cdc.gov/phil/home.asp ID#: 70 US Department of Health and Human ServicesDuchenne Muscular DystrophyImlifidase enables gene therapy in Duche...Initial clinical data indicate that the recombinant cysteine protease imlifidase, developed by Hansa Biopharma AB, may significantly reduce levels of anti-AAV antibodies, potentially enabling adeno-associated … more ➔
Daniel Torok, Public domain, via Wikimedia CommonsUS Pharma Prices Trump sets 60-day deadline for US pharma...US President Donald Trump has set a deadline in a letter to the CEOs of the 17 leading Big Pharma companies for the announced reduction of prescription drug prices. more ➔
Maxwell Hamilton - wikipedia.orgCOPDGSK licenses COPD blockbuster in US$12bn...Following Merck Sharp & Dohme (MSD)’s US$10bn acquisition of Verona Pharma and its potential COPD blockbuster Ohtuvayre®, GlaxoSmithKline (GSK) has secured a US$12bn deal for another PDE3/PDE4 inhi … more ➔
Lift Biosciences LtdAllogeneic cancer immunotherapyLIfT BioSciences Ltd receives €12m for c...LIfT BioSciences Ltd, active in London, Galway and Houston, has been awarded a grant of €12m from the Disruptive Technologies Innovation Fund (DTIF) to support the clinical translation of its Immuno-Modulatory … more ➔
Celt Studio - adobe stock.comUS-EU trade conflictImport tariff of 15%: significant implic...In the ongoing dispute over US import tariffs on European pharmaceuticals, the European Commission has acquiesced to a 15% tariff on EU pharmaceutical exports to the United States, as well as to the … more ➔
Bruno Coelho - stock.adobe.com Lung cancerBayer targets leading position in HER2-p...The potential blockbuster HER2 tyrosine kinase inhibitor sevabertinib, developed jointly by Bayer AG and the Broad Institute, is expected to be submitted for regulatory approval in China in Q3 2025 for … more ➔
lkov - adobe stock photo
Dewpoint Therapeutics Inc
adobe stock photos - ndomble 
Ragon Institute/MIT
Dr. Edwin P. Ewing, Jr. - http://phil.cdc.gov/phil/home.asp ID#: 70 US Department of Health and Human Services
Daniel Torok, Public domain, via Wikimedia Commons
Maxwell Hamilton - wikipedia.org
Lift Biosciences Ltd
Celt Studio - adobe stock.com
Bruno Coelho - stock.adobe.com